| Literature DB >> 29976156 |
Marie Patrice Halle1, Anais Mfoula Edjomo2, Hermine Fouda3, Hilaire Djantio4, Noel Essomba2, Gloria Enow Ashuntantang3.
Abstract
BACKGROUND: There are conflicting reports on the impact of HIV in the era of combined antiretroviral (c-ART) on survival of patient with ESKD. We aimed to compare the one-year survival of HIV positive patients to that of their HIV negative counterparts with ESKD on maintenance haemodialysis in Cameroon.Entities:
Keywords: Cameroon; End stage kidney disease; HIV patients; Haemodialysis; Survival
Mesh:
Year: 2018 PMID: 29976156 PMCID: PMC6034298 DOI: 10.1186/s12882-018-0964-8
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristic of the study population (n = 114)
| Variables | HIV- | HIV + | p | |
|---|---|---|---|---|
| Gender n (%) | ||||
| Female | 30 (52.6) | 30 (52.6) | ||
| Male | 27 (47.4) | 27 (47.4) | 1 | |
| Age (years) | Mean ± SDa | 46.25 ± 11.41 | 46.00 ± 11.40 | 0.909 |
| Matrimonial status n (%) | ||||
| Married | 42 (73.7) | 27 (47.4) | ||
| Non married | 15 (26.3) | 30 (52.6) |
| |
| Co morbidity n (%) | ||||
| History of hypertension | 51 (89.5) | 35 (61.4) |
| |
| History of diabetes | 15 (26.3) | 9 (15.8) | 0.168 | |
| Hepatitis B infection | 3 (5.3) | 4 (7.0) | 1 | |
| Hepatitis C infection | 8 (14.0) | 8 (14.0) | 1 | |
| Baseline nephropathy | ||||
| HIVb | 0 (0.0) | 29 (50.9) | ||
| CGNc | 19 (33.3) | 8 (14.0) | ||
| Unknown | 11 (19.3) | 11 (19.3) | ||
| Hypertension | 15 (26.3) | 7 (12.3) | ||
| Diabetes | 12 (21.1) | 2 (3.5) |
| |
| Vascular access at initiation n (%) | ||||
| Temporary CVCd | 45 (78.9) | 52 (91.2) | ||
| AVFe | 12 (21.1) | 5 (8.8) | 0.066 | |
| Biologic Data | Mean ± SDa | |||
| Haemoglobin | 7.86 ± 1.98 | 7.12 ± 1.70 |
| |
| Calcemia | 76.59 ± 14.78 | 73.64 ± 16.78 | 0.370 | |
| Phosphoremia | 71.13 ± 28.84 | 67.88 ± 35.47 | 0.639 | |
| CD4 count | ||||
| Median (IQRf) | 212 (138–455) | – | – | |
| CD4 count<200cells/mm3 n (%) | 23 (46.9) | – | – | |
| Use of c-ARTg n (%) | 44 (77.2) | – | – | |
| Drug regimen n (%)( | – | – | ||
| 1st line | 37 (84.1) | – | – | |
| 2nd line | 6 (13.6) | – | – | |
| Hospitalisation rate n (%) | 10 (17.5) | 12 (21.1) | 0.635 | |
aSD Standard deviation, bHIV Human immune deficiency virus, cCGN Chronic glomerulonephritis, dCVC Central venous catheter, eAVF Arterio- venous fistula, fIQR Interquartile range, gc-ART Combined antiretroviral treatment
Values in bold are significant (p < 0.05)
Mortality and survival rate
| All patients | HIV- | HIV+ | HRa (95% CIb) | ||
|---|---|---|---|---|---|
| Mortality rate | 34 (29.8) | 12 (21.1) | 22 (38.6) | 2.05 (1.03–4.08) |
|
HR Hazard ratio(Unadjusted univariate Cox regression analysis), b: Confidence interval
Value in bold is significant (p < 0.05)
Fig. 1Kaplan Meier Survival curve; p value = 0.052 for log rank test, ß probability = 0.84
Presumed causes of death
| Causes of death | All patients | HIV- | HIV+ | |
|---|---|---|---|---|
| Sepsis | 14 (41.2) | 6 (50.0) | 8 (36.4) | 0.440 |
| Tuberculosis | 4 (11.8) | 0 (0.0) | 4 (18.2) | 0.273 |
| Withdrawal from Dialysis | 4 (11.8) | 0 (0.0) | 4 (18.2) | 0.273 |
| Gastro intestinal bleeding | 4 (11.8) | 3 (25.0) | 1 (4.5) | 0.115 |
| Hemorrragic stroke | 1 (2.9) | 0 (0.0) | 1 (4.5) | 1 |
| Pulmonary edema | 1(2.9) | 0(0.0) | 1(4.5) | 1 |
| Cancer of the kidney | 1(2.9) | 0(0.0) | 1(4.5) | 1 |
| Undetermined | 5 (14.7) | 3 (25.0) | 2(9.0) | 0.677 |
Predictors of death amongst HIV positive patients (Cox regression analysis)
| Variable | Basic models | Final models | ||
|---|---|---|---|---|
| HRa (95% CIb) | p | HRa (95% CI) | p | |
| Age | 1.02 (0.98–1.06) | 0.284 | 1.02 (0.98–1.06) | 0.452 |
| Gender (female vs male) | 1.00 (0.40–2.52) | 0.993 | 1.09 (0.44–2.72) | 0.857 |
| Unemployed | 1.24 (0.53–2.89) | 0.619 | 1.95 (0.76–4.97) | 0.165 |
| Absence of nephrology follow up before 1st dialysis | 1.14 (0.49–2.65) | 0.757 | 0.93 (0.39–2.19) | 0.863 |
| Dialysis initiation with a temporary catheter | 2.30 (0.31–17.09) | 0.417 | 3.31 (0.42–25.94) | 0.254 |
| Hypertension | 1.03 (0.43–2.48) | 0.949 | 0.89 (0.33–2.42) | 0.825 |
| Diabetes | 2.32 (0.87–6.19) | 0.094 | 1.76 (0.64–4.85) | 0.271 |
| Hepatitis B | 0.52 (0.07–3.90) | 0.528 | 0.21 (0.03–1.81) | 0.156 |
| Hepatitis C | 1.39 (0.44–4.39) | 0.572 | 1.40 (0.43–4.61) | 0.579 |
| No cARTc at dialysis initiation | 2.99 (1.27–7.06) |
| 2.66 (1.09–6.50) |
|
HR Hazard ratio, b: Confidence interval, c: cART Combined anti-retroviral treatment
Basic models are adjusted for age, and final models are adjusted for age and all predictors with a p value < 0.1 in the basic models (diabetes, absence of c-ART at dialysis initiation)
Values in bold are significant (p < 0.05)